CO2021014260A2 - Formas sólidas de un inhibidor de glyt1 - Google Patents

Formas sólidas de un inhibidor de glyt1

Info

Publication number
CO2021014260A2
CO2021014260A2 CONC2021/0014260A CO2021014260A CO2021014260A2 CO 2021014260 A2 CO2021014260 A2 CO 2021014260A2 CO 2021014260 A CO2021014260 A CO 2021014260A CO 2021014260 A2 CO2021014260 A2 CO 2021014260A2
Authority
CO
Colombia
Prior art keywords
solid forms
inhibitor
glyt1 inhibitor
glyt1
glycine transporter
Prior art date
Application number
CONC2021/0014260A
Other languages
English (en)
Inventor
Peter Sieger
Joe Ju Gao
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO2021014260A2 publication Critical patent/CO2021014260A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan formas sólidas de un inhibidor del transportador de glicina-1 (GlyT1). La invención también se refiere a métodos para fabricar estas formas sólidas, composiciones farmacéuticas que comprenden estas formas sólidas y su uso para afecciones médicas que responden al tratamiento con un inhibidor del transportador de glicina-1.
CONC2021/0014260A 2019-05-01 2021-10-26 Formas sólidas de un inhibidor de glyt1 CO2021014260A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01
PCT/US2020/030580 WO2020223419A1 (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Publications (1)

Publication Number Publication Date
CO2021014260A2 true CO2021014260A2 (es) 2021-10-29

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014260A CO2021014260A2 (es) 2019-05-01 2021-10-26 Formas sólidas de un inhibidor de glyt1

Country Status (23)

Country Link
US (2) US11447474B2 (es)
EP (1) EP3962911A1 (es)
JP (1) JP2022530630A (es)
KR (1) KR20220004174A (es)
CN (1) CN113784966A (es)
AR (1) AR118839A1 (es)
AU (1) AU2020266566A1 (es)
BR (1) BR112021020883A2 (es)
CA (1) CA3138288A1 (es)
CL (1) CL2021002837A1 (es)
CO (1) CO2021014260A2 (es)
CR (1) CR20210545A (es)
DO (1) DOP2021000224A (es)
EA (1) EA202192925A1 (es)
EC (1) ECSP21082195A (es)
IL (1) IL287630A (es)
JO (1) JOP20210295A1 (es)
MA (1) MA55801A (es)
MX (1) MX2021013341A (es)
PE (1) PE20212263A1 (es)
SG (1) SG11202111972YA (es)
TW (1) TW202106680A (es)
WO (1) WO2020223419A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
JP2023537963A (ja) * 2020-08-13 2023-09-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 統合失調症に伴う認知機能障害に対する処置法
CA3195702A1 (en) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Process of reworking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
EP1680124B1 (en) * 2003-10-14 2017-05-31 Pfizer Products Inc. Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
WO2010065701A1 (en) * 2008-12-04 2010-06-10 Sanofi-Aventis Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
MX2011006845A (es) * 2008-12-29 2011-08-04 Univ Vanderbilt Inhibidores de glyt1 biciclicos 3.1.0 y metodos para elaboracion y utilizacion de los mismos.
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2018199235A1 (ja) * 2017-04-27 2018-11-01 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
DOP2021000224A (es) 2021-12-15
WO2020223419A1 (en) 2020-11-05
MA55801A (fr) 2022-03-09
CA3138288A1 (en) 2020-11-05
ECSP21082195A (es) 2021-12-30
JOP20210295A1 (ar) 2023-01-30
CN113784966A (zh) 2021-12-10
CR20210545A (es) 2021-12-23
MX2021013341A (es) 2021-11-17
BR112021020883A2 (pt) 2022-04-19
PE20212263A1 (es) 2021-11-29
AR118839A1 (es) 2021-11-03
US11447474B2 (en) 2022-09-20
IL287630A (en) 2021-12-01
EP3962911A1 (en) 2022-03-09
TW202106680A (zh) 2021-02-16
JP2022530630A (ja) 2022-06-30
CL2021002837A1 (es) 2022-07-29
SG11202111972YA (en) 2021-11-29
KR20220004174A (ko) 2022-01-11
AU2020266566A1 (en) 2021-11-11
US20220332710A1 (en) 2022-10-20
EA202192925A1 (ru) 2022-03-23
US20200347041A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
CO2021003036A2 (es) Compuestos de anillo fusionado
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
PH12020550051A1 (en) Glp-1 compositions and uses thereof
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CL2020002597A1 (es) Métodos para preparar composiciones proteicas estables
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
PE20180691A1 (es) Variantes de il-37
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
BR112017018618A2 (pt) odorizante de osmanthus
EA201791937A1 (ru) Противовоспалительные полипептиды
CO2020003134A2 (es) Moduladores de la expresión de enac
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello